Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ioflupane I-123

FDA-approved product (solution, intravenous), marketed as Datscan, Ioflupane I-123.

Registered studies
36
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ioflupane I-123
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormality of movement
  • Alzheimer disease
  • Computed tomography
  • Dementia
  • Lewy body dementia
  • Movement disorder
  • Multiple system atrophy
  • Neuroimaging measurement
  • Parkinson disease
  • Radiologic finding

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Iodine (123i) compounds
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ioflupane I-123 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ioflupane I-123 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

    NCT01089283 · start 2010-03

    Registered record
    Registry ID
    NCT01089283
    Conditions
    Parkinson Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-03
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies

    NCT00917709 · start 2009-05

    Registered record
    Registry ID
    NCT00917709
    Conditions
    Dementia With Lewy Bodies
    Interventions
    Imaging with IBVM; Imaging with DATSCAN; neuropsychological evaluation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-05
    Completion
    2013-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia With Lewy Bodies
    InterventionImaging with IBVM; Imaging with DATSCAN; neuropsychological evaluation
    PhaseNot applicable
    Registry statusCompleted

  • Dopaminergic Loss and Pain in Parkinson's Disease

    NCT00940914 · start 2009-03

    Registered record
    Registry ID
    NCT00940914
    Conditions
    Parkinson's Disease; Pain
    Interventions
    ioflupane 123I (DATSCAN®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Pain
    Interventionioflupane 123I (DATSCAN®)
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms

    NCT00382967 · start 2006-10

    Registered record
    Registry ID
    NCT00382967
    Conditions
    Parkinsonian Syndromes
    Interventions
    DaTSCAN SPECT imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2011-01
    Enrolment
    273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinsonian Syndromes
    InterventionDaTSCAN SPECT imaging
    PhasePhase 4
    Registry statusCompleted

  • Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

    NCT00129181 · start 2005-01

    Registered record
    Registry ID
    NCT00129181
    Conditions
    Parkinson Disease; Parkinsonian Syndrome
    Interventions
    cabergoline; carbidopa/levodopa; DATscan and SPECT imaging
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-01
    Completion
    2007-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Parkinsonian Syndrome
    Interventioncabergoline; carbidopa/levodopa; DATscan and SPECT imaging
    PhaseNot applicable
    Registry statusCompleted

  • Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

    NCT00209456 · start 2003-11

    Registered record
    Registry ID
    NCT00209456
    Conditions
    Lewy Body Dementia; Non-DLB Dementia; Alzheimer's; Vascular Dementia
    Interventions
    DatSCAN
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    Not recorded
    Enrolment
    326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLewy Body Dementia; Non-DLB Dementia; Alzheimer's; Vascular Dementia
    InterventionDatSCAN
    PhasePhase 3
    Registry statusCompleted